6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 6 of 6 clinical reviews.
A clinical comparison of resmetirom (Rezdiffra) and pioglitazone (Actos) for MASLD/MASH across special populations including type 2 diabetes, obesity, post-menopausal women, and advanced fibrosis.
A head-to-head clinical comparison of resmetirom (Rezdiffra) and pioglitazone (Actos) for MASLD/MASH, including the evidence base, mechanistic rationale, and safety considerations for combination use.
A head-to-head clinical comparison of resmetirom (Rezdiffra) and pioglitazone (Actos) for long-term NASH/MASLD response, covering trial data, durability, weight effects, fibrosis outcomes, and when to switch.
A head-to-head comparison of resmetirom (Rezdiffra) and pioglitazone (Actos) for MASLD/MASH, covering trial data, real-world evidence, dosing, side effects, and when to switch.
A detailed clinical comparison of resmetirom (Rezdiffra) and pioglitazone (Actos) titration protocols, side-effect profiles, and patient selection for MASLD/MASH treatment.
A clinical comparison of resmetirom (Rezdiffra) and pioglitazone (Actos) for MASLD/MASH, including what to do when one drug fails, how to switch, and when to combine both.